NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC)

**Drug and Indication:**

|  |  |
| --- | --- |
| **Generic drug name:** |  |
| **Formulations:** |  |
| **Intended indication:** |  |
| **Status of medicine or treatment:** |  |

**Responsibilities of Acute Care/Specialist Service (Consultant):**

* TEXT

**Responsibilities of Primary Care (General Practitioner):**

* TEXT

**Responsibilities of Patient:**

* TEXT

**Additional Responsibilities:**

* TEXT

**Cautions:**

**Contraindications:**

**Typical Dosage Regimens:**

|  |  |
| --- | --- |
| **Route of administration:** |  |
| **Recommended starting dose:** |  |
| **Titration of dose:** |  |
| **Maximum dose:** |  |
| **Adjunctive treatment regimen:** |  |
| **Conditions requiring dose adjustment:** |  |
| **Usual response time:** |  |
| **Duration of treatment** |  |

**Significant Drug Interactions:**

* TEXT

**Undesirable Effects:**

* TEXT

|  |  |
| --- | --- |
| **ADR details** (where possible indicate if common, rare or serious) | **Management of ADR** |
|  |  |
|  |  |
|  |  |
|  |  |

**Baseline Investigations:**

* TEXT

**Monitoring (Primary Care):**

* The following monitoring is to be undertaken in Primary Care

|  |  |  |  |
| --- | --- | --- | --- |
| **Monitoring Parameters** | **Frequency** | **Laboratory results** | **Action to be taken** |
|  |  |  |  |
|  |  |  |  |

**Monitoring (Acute Sector):**

* The following monitoring is to be undertaken in Acute Care

|  |  |  |  |
| --- | --- | --- | --- |
| **Monitoring Parameters** | **Frequency** | **Laboratory results** | **Action to be taken** |
|  |  |  |  |
|  |  |  |  |

**Pharmaceutical Aspects:**

* TEXT

**Cost:**

* TEXT

**Information for Community Pharmacist:**

* TEXT

**Acute Care/Specialist Service Contact Information:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Designation** | **Acute Site** | **Department phone number** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Supporting Documentation:**

* TEXT